RANKINGS
Lowest P/S — Healthcare
Price-to-Sales ratio measures valuation relative to revenue.
59 companies with P/S Ratio data.
Ranked by P/S Ratio(59)
| # | Ticker | Name | Market Cap | P/S Ratio |
|---|---|---|---|---|
| 1 | SNYR | $2M | 0.1 | |
| 2 | IMCC | $2M | 0.1 | |
| 3 | TRIB | $8M | 0.1 | |
| 4 | MITQ | $6M | 0.3 | |
| 5 | AUNA | $378M | 0.3 | |
| 6 | CCM | $21M | 0.3 | |
| 7 | AYTU | $24M | 0.4 | |
| 8 | SNDL | $336M | 0.5 | |
| 9 | BON | $9M | 0.5 | |
| 10 | WOK | $6M | 0.6 | |
| 11 | NIVF | $3M | 0.6 | |
| 12 | MDXH | $69M | 0.6 | |
| 13 | BMGL | $9M | 1.0 | |
| 14 | BMRA | $6M | 1.2 | |
| 15 | PHG | $26.3B | 1.3 | |
| 16 | APM | $570,062.5 | 1.3 | |
| 17 | SCNI | $2M | 1.4 | |
| 18 | BNR | $105M | 1.4 | |
| 19 | GIB | $15.4B | 1.4 | |
| 20 | PLSM | $17M | 1.5 | |
| 21 | INNV | $1.5B | 1.6 | |
| 22 | AVNS | $1.2B | 1.6 | |
| 23 | GLXG | $6M | 1.8 | |
| 24 | INTJ | $5M | 2.2 | |
| 25 | INMD | $854M | 2.3 | |
| 26 | CLGN | $5M | 2.3 | |
| 27 | ICCM | $8M | 2.3 | |
| 28 | POCI | $48M | 2.5 | |
| 29 | PDEX | $207M | 2.8 | |
| 30 | VALN | $622M | 3.1 | |
| 31 | ALC | $34.9B | 3.4 | |
| 32 | EVAX | $26M | 3.5 | |
| 33 | ZTG | $11M | 3.5 | |
| 34 | CGEN | $261M | 3.6 | |
| 35 | JLHL | $141M | 4.0 | |
| 36 | QGEN | $9.0B | 4.3 | |
| 37 | STVN | $6.1B | 4.5 | |
| 38 | SPPL | $21M | 4.6 | |
| 39 | CLLS | $358M | 4.9 | |
| 40 | NNOX | $66M | 5.1 | |
| 41 | EUDA | $45M | 6.6 | |
| 42 | ANAB | $1.7B | 7.3 | |
| 43 | RYOJ | $71M | 7.6 | |
| 44 | FOFO | $18M | 7.9 | |
| 45 | ACCL | $39M | 8.0 | |
| 46 | ZJYL | $173M | 8.4 | |
| 47 | MDWD | $171M | 10.1 | |
| 48 | ITOC | $6M | 10.6 | |
| 49 | NVMI | $11.8B | 13.4 | |
| 50 | CAMT | $6.8B | 13.6 | |
| 51 | BWAY | $579M | 14.1 | |
| 52 | BRTX | $5M | 14.6 | |
| 53 | EGG | $79M | 17.8 | |
| 54 | POAS | $3M | 21.5 | |
| 55 | IPHA | $249M | 24.4 | |
| 56 | LICN | $20M | 24.8 | |
| 57 | NNNN | $341M | 39.5 | |
| 58 | SUPX | $423M | 117.6 | |
| 59 | YDES | $274M | 459.3 |
How to turn this ranking into valuation work
Start with the company page
Validate business quality, margins, capital structure, and the current valuation context before relying on a single multiple.
Then validate WACC
A cheap multiple does not guarantee a sensible discount rate. Check cost of capital before finalizing DCF assumptions.
Finish with DCF
Use the matching DCF page to test intrinsic value so multiples, discount rates, and cash-flow assumptions stay connected.
P/S Ratio Rankings in Other Sectors
Data updated daily · Source: SEC EDGAR, Polygon.io